AbbVie’s Modest Phase 3 HS Win Prompts Avalo Downgrades
AbbVie’s Phase 3 HS data fell short of expectations, prompting two firms to downgrade Avalo Therapeutics and lower confidence in IL-1 approaches.
AbbVie’s Phase 3 HS data fell short of expectations, prompting two firms to downgrade Avalo Therapeutics and lower confidence in IL-1 approaches.
TD Cowen calls Phase 3 intismeran + Keytruda results “compelling” and in the exceptional range. Wells Fargo says RFS exceeded expectations.
EQT has submitted a binding offer of more than $50 per share for Qiagen in a potential $10 billion takeover. KKR has also bid as shares jump.
Citrini’s Claude Science experiment shows AI can design protein binders in days, shifting the bottleneck to real labs and lifting demand for Charles River and Revvity.
Eli Lilly, Merck, AbbVie, and UnitedHealth rose as markets fell on stronger inflation data, highlighting healthcare’s defensive strength.
An FDA multi-discipline review showed daraxonrasib’s 32% response was stronger in G12V than G12D. RVMD dropped; Stifel keeps Buy.